Telmisartan

Generic Name: Telmisartan

Brand Names: Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₀N_₄O_₂

CAS Number: 144701-48-4

Unique Ingredient Identifier: U5SYW473RQ

Background: Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.

Indication: Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension

Clinical Trials

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

Phase 3

Terminated

Conditions: Cognitive Decline
Intracerebral Hemorrhage
Dementia, Vascular
Cerebral Small Vessel Diseases
Hypertension
Stroke Hemorrhagic

Interventions: Drug: Placebo oral capsule
Drug: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg

First Posted Date: 2018-12-24

Last Posted Date: 2021-04-01

Lead Sponsor: The George Institute

Target Recruit Count: 1

Registration Number: NCT03785067

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands
🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

and more 1 locations

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study

Not Applicable

Terminated

Conditions: Intracerebral Hemorrhage
Stroke
Cerebral Small Vessel Diseases
Vascular Dementia
Hypertension

Interventions: Drug: telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg
Drug: Placebo oral capsule

First Posted Date: 2018-12-21

Last Posted Date: 2021-05-25

Lead Sponsor: The George Institute

Target Recruit Count: 4

Registration Number: NCT03783754

Locations: 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺
Sunshine Coast University Hospital, Birtinya, Queensland, Australia

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Telmisartan
Drug: Micardis

First Posted Date: 2018-10-15

Last Posted Date: 2018-12-27

Lead Sponsor: Pharmtechnology LLC

Target Recruit Count: 26

Registration Number: NCT03705533

Locations: 🇨🇦
Algorithme Pharma, An Altasciences Company, Mount-Royal, Quebec, Canada

Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg

First Posted Date: 2018-09-07

Last Posted Date: 2024-11-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 67

Registration Number: NCT03662620

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollanam-do, Korea, Republic of

Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

Phase 3

Completed

Conditions: Hypertension With Hyperlipidemia

Interventions: Drug: Telmisartan/Amlodipine
Drug: Rosuvastatin
Drug: Telmisartan

First Posted Date: 2018-06-25

Last Posted Date: 2018-06-25

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 134

Registration Number: NCT03566316

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Phase 4

Conditions: Chronic Kidney Disease
Proteinuria

Interventions: Drug: Telmisartan 40mg
Drug: Telmisartan/Rosuvastatin 40/10mg

First Posted Date: 2018-06-08

Last Posted Date: 2020-12-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 374

Registration Number: NCT03550859

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of

and more 13 locations